"Pharmaceutical headline king" under the wind lost money drugstore owner live with goods for a year.

(2020/07/01) Inovio's new crown vaccine phase 1 clinical immune response rate of 94% share price but fell 15%; Yangzijiang's position is stable Hengrui growth rate bright-eyedOn June 30, Inovio, an American biotech company, disclosed preliminary findings of its experimental new coronavaccinee, INO-4800, announcing that 94 percent of subjects in Phase 1 clinical trials showed an overall immune responseHowever, capital markets did not seem satisfied with the results of the test, with Inovio's shares falling by more than 20 per cent at one point and closing down 15 per cent by the close on June 30One of the core selling points of the INO-4800 is that it can be transported and stored at room temperature2019, the total size of the live-streaming e-commerce industry reached 433.8 billion yuanIn contrast to the particularity of products and services and the scale of policy supervision, the live broadcast in the field of medicine is tepidIt's hard to do, but pharmacy owners aren't willing to leaveWhat are they looking for?live is to maintain user stickinessJune 29, Liaoning Province, medicine and medical supplies centralized procurement network issued "on the medical supplies with the same price results to implement the promotion of comprehensive management of medical supplies notice." The province's cities unified on July 1, 2020 at 0:00 to implement medical supplies with the same price results, the original "Liaoning Province medical supplies sunshine procurement information library" will be closedsupplies price is too high hospitals have to bargain twiceOn June 29,, the Zhejiang Provincial Health Insurance Bureau issued a notice to promote the full coverage reform plan of the standard of payment of medical insurance drugs in Zhejiang Province to promote the function of the centralized procurement platform for drugsThe program points out that the implementation of the program for all public medical institutions in the province, medical insurance fixed-point private medical institutions and medical insurance fixed-point retail pharmacies15% of the mark-up or become a uniform standardrecently, Yangzijiang's hydrochloric acid nabmorphine injection 3 class imitation listing application for the second acceptance number (CYHS2000430) to obtain CDE, in January 2020 to obtain the acceptance number (CYHS2000059) is being reviewed and approved, it can be seen that Yangzijiang attaches great importance to the product, the product is currently only people to obtain approvalBayer, the leader, maintains a market share of more than 80% more than 100 teams around the world are racing to develop a new crown vaccine, who revealed at a routine press conference on New Crown Pneumonia that there are more than 200 candidate vaccines worldwide, 15 of which are undergoing human clinical trials But the bad news is that even if the vaccine is approved, it will not be rolled out globally immediately because of the lack of glass vials needed to store the vaccine it's time to enforce medium-boron silicon glass On June 30, , the FDA's Center for Biological Product Evaluation and Research (CBER) released the Industry Guide: COVI9-19 Preventive Vaccine Development and Licensing document to help biopharmaceutical companies in clinical development and regulatory approval of COVID-19 preventive vaccines applicants should have a drug alert plan in place before the vaccine is available.